Chelation therapy in lead nephropathy.
Although treatment has been well defined for childhood lead poisoning and for industrial lead exposure, the treatment of lead nephropathy has been poorly studied. The available chelating agents are reviewed and the results of treatment in 17 cases of lead nephropathy are shown. It is concluded that lead nephropathy should be recognized early and treated energetically, as this may stabilize or improve renal function. Since EDTA is excreted much like creatinine, the dosage must be reduced proportionately in response to elevated serum creatinine levels in the patient with renal failure.
D058186:Acute Kidney Injury / Q000139:chemically induced; D000284:Administration, Oral; D002614:Chelating Agents / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004112:Dimercaprol / Q000627:therapeutic use; D003875:Drug Eruptions / Q000139:chemically induced; D004359:Drug Therapy, Combination; D004492:Edetic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000473:pathology*; D007854:Lead / Q000652:urine; D007855:Lead Poisoning / Q000188:drug therapy*; D008297:Male; D010396:Penicillamine / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000139:chemically induced
D002614:Chelating Agents; D004112:Dimercaprol; D007854:Lead; D004492:Edetic Acid; D003404:Creatinine; D010396:Penicillamine